{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T09:32:14Z","timestamp":1786354334000,"version":"build-2736575974"},"reference-count":12,"publisher":"Ovid Technologies (Wolters Kluwer Health)","content-domain":{"domain":["www.ahajournals.org"],"crossmark-restriction":true},"short-container-title":["Circ: Heart Failure"],"abstract":"<jats:sec>\n                    <jats:title>BACKGROUND:<\/jats:title>\n                    <jats:p>Frequent transthoracic echocardiograms (TTEs) are required to monitor for left ventricular systolic dysfunction (LVSD) in patients with obstructive hypertrophic cardiomyopathy receiving myosin inhibitors. This requirement may be cumbersome and limit access in underserved and rural areas. The objective of this study was to evaluate the performance of an artificial intelligence (AI)\u2013enabled ECG tool in predicting LVSD in hypertrophic cardiomyopathy patients on mavacamten.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>METHODS:<\/jats:title>\n                    <jats:p>At Morristown Medical Center\/Atlantic Health, 147 patients initiated on mavacamten between June 2022 and June 2025 underwent ECGs and TTEs at baseline and clinically available follow-up visits. A validated AI\u2013enabled ECG algorithm predicted the probability of LVSD. Sensitivity, specificity, negative predictive value, positive predictive value, and area under the curve were calculated for left ventricular ejection fraction &lt;50%, with CIs accounting for repeated paired ECG-TTE observations within patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS:<\/jats:title>\n                    <jats:p>In 147 patients, mean age was 65\u00b114 years; 44% were male. Among 453 paired ECG-TTE observations, 8 LVSD event observations occurred. At an AI probability threshold of 20%, sensitivity was 100% (95% CI, 68%\u2013100%), specificity was 75% (95% CI, 69%\u201382%), positive predictive value was 7% (95% CI, 3%\u201311%), and negative predictive value was 100% (95% CI, 99%\u2013100%). The area under the curve was 0.94 (95% CI, 0.90\u20130.98). Patient-level classifications between AI\u2013enabled ECG and echo-confirmed LVSD were concordant in 127 of 147 patients (86%), inconclusive in 17 of 147 (12%), and discordant in 3 of 147 (2%).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSIONS:<\/jats:title>\n                    <jats:p>In this single-center exploratory cohort of patients with obstructive hypertrophic cardiomyopathy receiving mavacamten, ECG-Vision left ventricular demonstrated high observed sensitivity and negative predictive value for TTE-defined LVSD, although estimates were imprecise because LVSD events were infrequent. These findings support prospective multicenter validation of AI\u2013enabled ECG as a potential adjunctive triage tool.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1161\/circheartfailure.126.014177","type":"journal-article","created":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T09:00:16Z","timestamp":1786352416000},"update-policy":"https:\/\/doi.org\/10.1161\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Utility of ECG-Vision for Surveillance of Left Ventricular Dysfunction in Patients With Hypertrophic Cardiomyopathy Initiated on Mavacamten"],"prefix":"10.1161","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3012-0380","authenticated-orcid":true,"given":"Aakash","family":"Bavishi","sequence":"first","affiliation":[{"name":"University of Illinois-Chicago (A.B.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0056-2877","authenticated-orcid":true,"given":"John","family":"Fritzlen","sequence":"additional","affiliation":[{"name":"University of Kansas Medical Center (J.F.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-9487-5319","authenticated-orcid":true,"given":"Marybeth","family":"Soutar","sequence":"additional","affiliation":[{"name":"Atlantic Health, Morristown, NJ (M.S., K.N., M.K., H.S., G.O., K.R., C.F., M.W.M.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4886-9050","authenticated-orcid":true,"given":"Kutaiba","family":"Nazif","sequence":"additional","affiliation":[{"name":"Atlantic Health, Morristown, NJ (M.S., K.N., M.K., H.S., G.O., K.R., C.F., M.W.M.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-9014-0925","authenticated-orcid":true,"given":"Margaret","family":"Kurnides","sequence":"additional","affiliation":[{"name":"Atlantic Health, Morristown, NJ (M.S., K.N., M.K., H.S., G.O., K.R., C.F., M.W.M.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather","family":"Speer","sequence":"additional","affiliation":[{"name":"Atlantic Health, Morristown, NJ (M.S., K.N., M.K., H.S., G.O., K.R., C.F., M.W.M.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Glenda","family":"Oyarce","sequence":"additional","affiliation":[{"name":"Atlantic Health, Morristown, NJ (M.S., K.N., M.K., H.S., G.O., K.R., C.F., M.W.M.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-8534-2178","authenticated-orcid":true,"given":"Karen","family":"Richards","sequence":"additional","affiliation":[{"name":"Atlantic Health, Morristown, NJ (M.S., K.N., M.K., H.S., G.O., K.R., C.F., M.W.M.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cara","family":"Flahive","sequence":"additional","affiliation":[{"name":"Atlantic Health, Morristown, NJ (M.S., K.N., M.K., H.S., G.O., K.R., C.F., M.W.M.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9255-4657","authenticated-orcid":true,"given":"Matthew W.","family":"Martinez","sequence":"additional","affiliation":[{"name":"Atlantic Health, Morristown, NJ (M.S., K.N., M.K., H.S., G.O., K.R., C.F., M.W.M.)."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,8,10]]},"reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2021.12.002"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)31792-X"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamacardio.2023.3342"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.124.012441"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cardfail.2024.10.230"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacadv.2025.102089"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.122.062646"},{"key":"e_1_3_3_9_2","volume-title":"Camzyos (Mavacamten) Capsules, for Oral Use","author":"Bristol-Myers Squibb","year":"2022","unstructured":"Bristol-Myers Squibb. Camzyos (Mavacamten) Capsules, for Oral Use [package insert]. 2022."},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.echo.2018.06.004"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2022.28.3.369"},{"key":"e_1_3_3_12_2","volume-title":"Variation in payer coverage of mavacamten (camzyos) for hypertrophic cardiomyopathy one year post-approval","author":"Value CftEo","unstructured":"Value CftEo, Health RI. Variation in payer coverage of mavacamten (camzyos) for hypertrophic cardiomyopathy one year post-approval. Tufts Medical Center."},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.123.034069"}],"container-title":["Circulation: Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ahajournals.org\/doi\/full\/10.1161\/CIRCHEARTFAILURE.126.014177","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T09:00:17Z","timestamp":1786352417000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ahajournals.org\/doi\/10.1161\/CIRCHEARTFAILURE.126.014177"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,10]]},"references-count":12,"alternative-id":["10.1161\/CIRCHEARTFAILURE.126.014177"],"URL":"https:\/\/doi.org\/10.1161\/circheartfailure.126.014177","relation":{},"ISSN":["1941-3289","1941-3297"],"issn-type":[{"value":"1941-3289","type":"print"},{"value":"1941-3297","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,10]]},"assertion":[{"value":"2026-01-04","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-28","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-08-10","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e014177"}}